Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

Histologically or cytologically confirmed cutaneous melanoma, classified as irresectable (stage III) or metastatic (stage IV) disease.
At least 18 years of age.
World Health Organization (WHO) Performance Status 0-1.
Measurable disease according to RECIST 1.1.
Starting treatment with standard-of-care combination immunotherapy (ipilimumab+nivolumab) as first line treatment.
Signed informed consent form

Uveal or mucosal melanoma (unknown primary melanoma is allowed).
Use of systemic immunosuppressive medications. Inhaled or topical steroids are permitted.
Use of adrenal replacement medications, e.g. hydrocortisone.
Use of melatonin agonists.
Prior systemic therapy for irresectable/metastatic melanoma (prior T-VEC is allowed)
Prior systemic therapy for resectable melanoma in the last 6 months (neo-adjuvant and adjuvant treatment is allowed if at least 6 months ago).
Use of investigational drugs.

Timing of Immunotherapy in Melanoma